Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Adjunctive therapy with oxcarbazepine in children with partial seizures

Glauser, T.A., Nigro, M., Sachdeo, R., Pasteris, L.A., Weinstein, S., Abou-Khalil, B., Frank, L.M., Grinspan, A., Guarino, T., Bettis, D., Kerrigan, J., Geoffroy, G., Mandelbaum, D., Jacobs, T., Mesenbrink, P., Kramer, L., D’Souza, J., the Oxcarbazepine Pediatric Study Group·2000·Neurology

Abstract

OBJECTIVE: To evaluate the safety and efficacy of oxcarbazepine (OXC) as adjunctive therapy in children with inadequately controlled partial seizures on one or two concomitant antiepileptic drugs (AEDs). BACKGROUND: OXC has shown antiepileptic activity in several comparative monotherapy trials in newly diagnosed patients with epilepsy, and in a placebo-controlled monotherapy trial in hospitalized patients evaluated for epilepsy surgery. DESIGN: A total of 267 patients were evaluated in a multicenter, randomized, placebo-controlled trial consisting of three phases: 1) a 56-day baseline phase (patients maintained on their current AEDs); 2) a 112-day double-blind treatment phase (patients received either OXC 30-46 mg/kg/day orally or placebo); and 3) an open-label extension phase. Data are reported only from the double-blind treatment phase; the open-label extension phase is ongoing. METHODS: Children (3 to 17 years old) with inadequately controlled partial seizures (simple, complex, and partial seizures evolving to secondarily generalized seizures) were enrolled. RESULTS: Patients treated with OXC experienced a significantly greater median percent reduction from baseline in partial seizure frequency than patients treated with placebo (p = 0.0001; 35% versus 9%, respectively). Forty-one percent of patients treated with OXC experienced a > or =50% reduction from baseline in partial seizure frequency per 28 days compared with 22% of patients treated with placebo (p = 0.0005). Ninety-one percent of the group treated with OXC and 82% of the group treated with placebo reported > or =1 adverse event; vomiting, somnolence, dizziness, and nausea occurred more frequently (twofold or greater) in the group treated with OXC. CONCLUSION: OXC adjunctive therapy administered in a dose range of 6 to 51 mg/kg/day (median 31.4 mg/kg/day) is safe, effective, and well tolerated in children with partial seizures.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.54.12.2237

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
Glauser, T. A., Nigro, M., Sachdeo, R., Pasteris, L. A., Weinstein, S., Abou-Khalil, B., Frank, L. M., Grinspan, A., Guarino, T., Bettis, D., Kerrigan, J., Geoffroy, G., Mandelbaum, D., Jacobs, T., Mesenbrink, P., Kramer, L., D’Souza, J., & the Oxcarbazepine Pediatric Study Group
Venue
Neurology
Published
2000-06-27
Volume
54
Issue
12
Pages
2237-2244
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2080109885
Cited by
173
References
0
FWCI
9.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjunctive therapy with oxcarbazepine in children with partial seizures. https://app.cochat.ai/papers/10.1212/wnl.54.12.2237
The paper
Glauser, T. A., Nigro, M., Sachdeo, R., Pasteris, L. A., Weinstein, S., Abou-Khalil, B., Frank, L. M., Grinspan, A., Guarino, T., Bettis, D., Kerrigan, J., Geoffroy, G., Mandelbaum, D., Jacobs, T., Mesenbrink, P., Kramer, L., D’Souza, J., & the Oxcarbazepine Pediatric Study Group. (2000). Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. https://doi.org/10.1212/wnl.54.12.2237

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.